The role of cyclin-dependent kinase inhibitors in adjuvant therapy of breast cancer

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Hormone receptor positive (HR+)/HER2-negative breast cancer (BC) is the most common subtype of breast cancer, accounting for approximately 70% of all breast cancer cases. Hormone therapy (tamoxifen) has been the basis of systemic treatment for such tumors since the 1980s. Further research began to focus on other endocrine therapeutic approaches, in particular, the return to ovarian ablation or conservative ovarian suppression in premenopausal women, as well as the use of aromatase inhibitors in postmenopausal women. Further administration of 3rd-line endocrinotherapy with fulvestrant in patients with advanced breast cancer improved progressive-free and overall survival. Overcoming endocrine resistance in the progression of the disease has become the basis of a new generation of endocrine therapy for progress in the therapy of hormone-receptor positive (HR+)/HER2-negative breast cancer. It turned out that cyclin-dependent kinases (CDK 4/6) are crucial for the progression of the cell cycle, and are an effective target in the treatment of breast cancer at various stages.

Full Text

Restricted Access

About the authors

V. F. Semiglazov

N.N. Petrov National Medical Research Center of Oncology

Email: bekkeldiyeva.n@bk.ru
ORCID iD: 0000-0003-0077-9619
Russian Federation, St. Petersburg

P. V. Krivorotko

N.N. Petrov National Medical Research Center of Oncology

Email: bekkeldiyeva.n@bk.ru
ORCID iD: 0000-0002-4898-9159
Russian Federation, St. Petersburg

Nestan B. Bekkeldiyeva

N.N. Petrov National Medical Research Center of Oncology

Author for correspondence.
Email: bekkeldiyeva.n@bk.ru
ORCID iD: 0009-0009-6055-720X
Russian Federation, St. Petersburg

A. V. Komyakhov

N.N. Petrov National Medical Research Center of Oncology

Email: bekkeldiyeva.n@bk.ru
ORCID iD: 0000-0002-6598-1669
Russian Federation, St. Petersburg

A. S. Emelyanov

N.N. Petrov National Medical Research Center of Oncology

Email: bekkeldiyeva.n@bk.ru
ORCID iD: 0000-0002-0528-9937
Russian Federation, St. Petersburg

A. O. Gorina

N.N. Petrov National Medical Research Center of Oncology

Email: bekkeldiyeva.n@bk.ru
ORCID iD: 0009-0003-9921-9642
Russian Federation, St. Petersburg

References

  1. Семиглазов В.Ф., Дашян Г.А., Семиглазов В.В. Ингибиторы ароматазы в первой линии эндокринотерапии больных метастатическим раком молочной железы. Русский медицинский журнал. 2008;13:935. [Semiglazov V.F., Dashyan G.A., Semiglazov V.V. Aromatase inhibitors in the first line of endocrine therapy for patients with metastatic breast cancer. Russian medical journal. 2008;13:935. (In Russ.)].
  2. Hamilton E., Infante J.R. Targeting CDK4/6 in patients with cancer. Cancer Treat Rev. 2016;45:129–38. doi: 10.1016/jctrv.2016.03.002.
  3. Cardoso F., Harbeck N., Fallowfield L., et al. Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23(Suppl. 7):vii11–9.
  4. Perou C.M., Sorlie T., Eisen M.B., et al. Molecular portraits of human breast tumours. Nature. 2000;406(6797):747–52.
  5. Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490(7418):61–70.
  6. Thangavel C., Dean J.L., Ertel A., et al. Therapeutically activating RB: reestablishing cell cycle control in endocrine therapy-resistant breast cancer. Endocr Relat Cancer. 2011; 18(3):333–45.
  7. Spring L., Bardia A., Modi S. Targeting the cyclin D-cyclin-dependent kinase (CDK) 4/6-retinoblastoma pathway with selective CDK 4/6 inhibitors in hormone receptor-positive breast cancer: rationale, current status, and future directions. Discov Med. 2016;21(113):65–74.
  8. Liu Y., Wu, J., Ji, Z. et al. Comparative efficacy and safety of different combinations of three CDK4/6 inhibitors with endocrine therapies in HR+/HER-2metastatic or advanced breast cancer patients: a network meta-analysis. BMC. Cancer. 2023;23:816. doi: 10.1186/s12885-023-11322-2.
  9. Hortobagyi G.N., Stemmer SM, Burris HA, Yap YS, Sonke GS, Paluch-Shimon S, et al. Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer. Ann Oncol. 2018;29(7):1541–7.
  10. Turner NC, Slamon D.J., Ro J., et al. Overall survival with palbociclib and fulvestrant in advanced breast Cancer. N Engl J Med. 2018;379(20):1926–36.
  11. Im S.A., Lu Y.S., Bardia A., et al. Overall survival with Ribociclib plus endocrine therapy in breast Cancer. N Engl J Med. 2019;381(4):307–16.
  12. Johnston S., Martin M., Di Leo A., et al. MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer. NPJ. Breast Cancer. 2019;5:5.
  13. Rugo H.S., Finn R.S., Dieras V., et al. Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up. Breast Cancer Res. Treat. 2019;174(3):719–29.
  14. Finn R.S., Boer K., Bondarenko I., et al. Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2advanced breast cancer (PALOMA-1, TRIO-18). Breast Cancer Res. Treat. 2020; 183(2):419–28.
  15. Sledge G.W., Toi M., Neven P., et al. The Effect of Abemaciclib Plus Fulvestrant on overall survival in hormone Receptor-Positive, ERBB2-Negative breast Cancer that progressed on endocrine Therapy-MONARCH 2: a Randomized Clinical Trial. JAMA. Oncol. 2020;6(1):116–24.
  16. Zhang Q.Y., Sun T., Yin Y.M., et al. MONARCH plus: abemaciclib plus endocrine therapy in women with HR+/HER2advanced breast cancer: the multinational randomized phase III study. Ther Adv Med Oncol. 2020;12:1758835920963925.
  17. Slamon D.J., Neven P., Chia S., et al. Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival. Ann Oncol. 2021;32(8):1015–24.
  18. Neven P., Fasching P.A., Chia S. et al. Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+/HER2 − advanced breast cancer receiving first-line ribociclib plus fulvestrant. Breast Cancer Res. 2023;25:103. Doi: /10.1186/s13058-023-01701-9.
  19. Johnston S.R.D., Harbeck N., Hegg R., et al. monarchE Committee Members and Investigators. Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE). J Clin Oncol. 2020;38(34):3987–98. doi: 10.1200/ JCO.20.02514.
  20. Cardoso F., Paluch-Shimon S., Senkus E., et al. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Ann Oncol. 2020;31(12):1623–49. doi: 10.1016/j.annonc.2020.09.010.
  21. Tripathy D., Im S.A., Colleoni M., et al. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. Lancet. Oncol. 2018;19(7):904-915. doi: 10.1016/S1470-2045(18)30292-4.
  22. Slamon D.J., Neven P., Chia S., et al. Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival. Ann Oncol. 2021;32(8):1015–24. doi: 10.1016/j.annonc.2021.05.353.
  23. Hortobagyi G., Stroyakovskiy D., et al. Abstract GS03-03. Presented at: San Antonio Breast Cancer Symposium; Dec 5–9, 2023; San Antonio.
  24. Finn R., Rugo H., Dieras V., et al. Overall survival (OS) with first-line palbociclib plus letrozole (PAL+LET) versus placebo plus letrozole (PBO+LET) in women with estrogen receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer (ER+/HER2ABC): Analyses from PALOMA-2. J Clin Oncol. 2022;40(17_suppl):LBA1003.
  25. Goetz M., et al. MONARCH 3: Final overall survival results of abemaciclib plus a nonsteroidal aromatase inhibitor as first-line therapy in patients with HR+, HER2advanced breast cancer. Presented at SABCS 2023 (December 06). GS01-12. Abstract 1643629.
  26. Lu Y.S., Mahidin E.I.B.M., et al. Primary results from the randomized Phase II RIGHT Choice trial of premenopausal patients with aggressive HR+/HER2advanced breast cancer treated with ribociclib + endocrine therapy vs physician’s choice combination chemotherapy. Presented at the 2022 San Antonio Breast Cancer Symposium (SABCS). December 6-10, 2022. Abstract #GS1-10.
  27. Azim H.A., El Saghir N.S., Yap Y.S., et al. 402P First-line ribociclib (RIB) + endocrine therapy (ET) vs combination chemotherapy (combo CT) in aggressive HR+/HER2advanced breast cancer (ABC): A subgroup analysis of patients (pts) with or without visceral crisis from the phase II RIGHT choice study. Ann Oncol. 2023;34(2): S350-S351.
  28. Loibl S., Marmé F., Martin M., et al. Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer-The Penelope-B Trial. J Clin Oncol. 2021;39(14):1518-1530. doi: 10.1200/JCO.20.03639.
  29. Gnant M., Dueck A.C., Frantal S., et al; PALLAS groups and investigators. Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03). J Clin Oncol. 2022;40(3):282-293. doi: 10.1200/JCO.21.02554.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies